CAS 284461-73-0
:Sorafenib
Beschreibung:
Sorafenib ist ein kleines Molekül, das als Tyrosinkinase-Inhibitor hauptsächlich zur Behandlung bestimmter Krebsarten, einschließlich Nierenzellkarzinom und hepatozellulärem Karzinom, eingesetzt wird. Seine chemische Formel lautet C21H16ClF2N3O3, und es weist eine komplexe Struktur auf, die einen Pyridinring, eine Phenylgruppe und eine Harnstoffeinheit umfasst. Sorafenib wirkt, indem es mehrere Kinasen hemmt, die an der Proliferation von Tumorzellen und der Angiogenese beteiligt sind, wobei es gezielt die RAF-Kinase und verschiedene Rezeptor-Tyrosinkinasen angreift. Dieser multi-target Ansatz hilft, die Signalwege zu stören, die das Wachstum und die Metastase von Krebs fördern. Sorafenib wird typischerweise oral verabreicht und hat eine moderate Bioverfügbarkeit, wobei seine Pharmakokinetik von Faktoren wie der Nahrungsaufnahme beeinflusst wird. Zu den häufigsten Nebenwirkungen gehören Müdigkeit, Durchfall und Hautreaktionen. Aufgrund seines Wirkmechanismus und seiner therapeutischen Anwendungen stellt Sorafenib einen bedeutenden Fortschritt in der gezielten Krebstherapie dar, obwohl seine Anwendung durch die Entwicklung von Resistenzen und die Notwendigkeit einer sorgfältigen Patientenüberwachung eingeschränkt sein kann.
Formel:C28H24ClF3N4O6S
InChl:InChI=1/C21H16ClF3N4O3.C7H8O3S/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25;1-6-2-4-7(5-3-6)11(8,9)10/h2-11H,1H3,(H,26,30)(H2,28,29,31);2-5H,1H3,(H,8,9,10)
InChI Key:InChIKey=MLDQJTXFUGDVEO-UHFFFAOYSA-N
SMILES:O(C=1C=C(C(NC)=O)N=CC1)C2=CC=C(NC(NC3=CC(C(F)(F)F)=C(Cl)C=C3)=O)C=C2
Synonyme:- 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-
- 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
- 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide 4-methylbenzenesulfonate
- 4-[4-[[4-Chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
- 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-Pyridinecarboxamide
- Bay 43-9006
- N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
- Nevaxar
- Sorafenib base
- Sorafenib
- SORAFENIB TOLSYLATE
- Sorafenib free base for research
- SORAFENIB-D3
- SORAFENIB MESYLATE
- BAY-43-900
- Sorafenib Tosylate(TINIBS)
- N-[4-Chloro-3-(trifluoromethyl)phenyl]-({4-[2-(N-methyl-carbamoyl)(4-pyridyloxy)]phenyl}amino)-carboxamide
- RAF1 KINASE INHIBITOR II
- SORAFENIB(FORR&DONLY)
- Sorafenib Tosylate for research
- Weitere Synonyme anzeigen
Sortieren nach
Reinheit (%)
0
100
|
0
|
50
|
90
|
95
|
100
14 Produkte.
Sorafenib
CAS:Formel:C21H16ClF3N4O3Reinheit:>98.0%(T)(HPLC)Farbe und Form:White to Light yellow powder to crystalMolekulargewicht:464.834-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
CAS:Formel:C21H16ClF3N4O3Reinheit:99%Farbe und Form:SolidMolekulargewicht:464.8249Sorafenib
CAS:Sorafenib (Bay 43-9006) is a multikinase inhibitor that inhibits Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57Formel:C21H16ClF3N4O3Reinheit:98% - 99.89%Farbe und Form:SolidMolekulargewicht:464.82Sorafenib
CAS:SorafenibFormel:C21H16ClF3N4O3Reinheit:98%Farbe und Form: white solidMolekulargewicht:464.82g/molSorafenib
CAS:Formel:C21H16ClF3N4O3Reinheit:≥ 95.0%Farbe und Form:White, off-white or light-yellow solidMolekulargewicht:464.83Sorafenib-d4
CAS:Kontrolliertes ProduktFormel:C21H12D4ClF3N4O3Farbe und Form:NeatMolekulargewicht:468.85Sorafenib - Bio-X ™
CAS:<p>Sorafenib is a drug that belongs to the class of multikinase inhibitors. It inhibits a number of kinases, including the Mcl-1 protein, which is involved in apoptosis along with blocking picolinic acid (PA), an endogenous metabolite involved in apoptosis signal transduction. Sorafenib also binds to epidermal growth factor receptor (EGFR) on the surface of cancer cells, inhibiting the production of proteins that are required for angiogenesis, thus blocking the formation of new blood vessels. Sorafenib may also inhibit P-glycoprotein (Pgp) activity. Overall, these cytotoxic effects give Sorafenib anti-tumor properties, inhibiting angiogenesis and cellular transformation, which are the two main processes of tumor growth and metastasis. Sorafenib has been shown to be effective against a range of solid tumors such as breast, prostate and lung cancers and is also used for the treatment of metastatic colorectal cancer and renal cell carcinoma. A combination therapy group found that sorafenib was more effective when used with interferon alfa-2b for the treatment of advanced renal cell carcinoma. Sorafenib also has the potential for drug interactions with other drugs that are metabolized by cytochrome P450 enzymes.<br>Sorafenib is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready to use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.</p>Formel:C21H16ClF3N4O3Reinheit:Min. 98%Farbe und Form:PowderMolekulargewicht:464.82 g/molSorafenib
CAS:<p>Sorafenib is a drug that belongs to the class of multikinase inhibitors. It inhibits a number of kinases, including the Mcl-1 protein, which is involved in apoptosis along with blocking picolinic acid (PA), an endogenous metabolite involved in apoptosis signal transduction. Sorafenib also binds to epidermal growth factor receptor (EGFR) on the surface of cancer cells, inhibiting the production of proteins that are required for angiogenesis, thus blocking the formation of new blood vessels. Sorafenib may also inhibit P-glycoprotein (Pgp) activity. Overall, these cytotoxic effects give Sorafenib anti-tumor properties, inhibiting angiogenesis and cellular transformation, which are the two main processes of tumor growth and metastasis. Sorafenib has been shown to be effective against a range of solid tumors such as breast, prostate and lung cancers and is also used for the treatment of metastatic colorectal cancer and renal cell carcinoma. A combination therapy group found that sorafenib was more effective when used with interferon alfa-2b for the treatment of advanced renal cell carcinoma. Sorafenib also has the potential for drug interactions with other drugs that are metabolized by cytochrome P450 enzymes.</p>Formel:C21H16ClF3N4O3Reinheit:Min. 98.0 Area-%Farbe und Form:White PowderMolekulargewicht:464.82 g/mol
![4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb%2FDA0039KS.jpg&w=3840&q=75)
